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INTRODUCTION
Alzheimer’s disease (AD) is a neurodegenerative process in the Central Nervous System (CNS) characterized by a progressive neuronal death in several
zones of the brain, in particular, cortical brain and hippocampus. The loss of immediate memory, a cognitive deterioration and behaviour disorders are
also characteristics of Alzheimer’s disease. The aetiology of the disease is already unknown and there is no existence of a treatment to stop the
pathologic process. Several hypothesis have been made and some implications have been found with the intention to explain phenomena and what is
going on AD.
PREVENTION AND TREATMENT
There is no effective treatment against AD. Findings and research for strategies which target the cholinergic system has led to the development of
cholinesterase inhibitors (AChEI) which diminish neuron loss (i.e. Rivastigmine). The synthesis of several antibodies or proteins that inhibit
aggregation of β-amyloid or tau protein respectively has been useful to halt the decline in cognitive function and improve it but with some
adverse effects (i.e. bapineuzumab, rember).
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CHOLYNERGIC HYPOTHESIS
The loss of acetylcholine (ACh) neurons is a hallmark in AD. Ach in
the synaptic cleft is catabolized by cholinesterases, implicated in
behavioural functions including learning and memory.
TAU PROTEIN HYPOTHESIS
Tau’s abnormal hyper-phosphorylation
in AD results in toxic gain of function
and formation of neurofibrillary tangles
of paired helical filaments (PHF).
PSEN IMPLICATION
Presenilins (code by PSEN) function as
the catalytic subunit of γ-secretase.
Some mutations in two conserved
aspartate (thought to be part of the
catalytic domain) cause loss of function.
AMYLOID 
HYPOTHESIS
Based on the
excessive
accumulation of
amyloid-β peptide in
aggregate forms
outside neurons by
cleavage of APP
which results in in the
production of
truncated Aβ peptide.
.
APOE IMPLICATION
Mutation of ε4 allele in APOE gene
coding for Apo-lipoprotein E
stimulates AD causing accelerated
cognitive decline with age and
memory loss. ApoE is important in
the metabolism of Aβ to carry it
from the brain to systemic
circulation for degrading.
PROGRESS IN ALZHEIMER’S THERAPY
Alzheimer’s therapies so far have revolved around retarding the progression of the disease rather than restoring the damaged neurons. However,
the recent trend is to focus on removing the causes of the disease with stem cell-based therapies. If the causes of AD are understood more deeply
and safer cell therapies are developed, AD could be conquered in the not too distant future.
CONCLUSIONS
Latest research direction of Alzheimer focuses on early diagnosis
(biomarker’s finding), given that the administered medication upon the
initial manifestation of the disease can help to maintain the quasi-normal
state of cognitive functions longer. Studies will show in the coming years
the potential effectiveness of these strategies, which are the expectancy
for the treatment of Alzheimer's disease.
